Author

Shannon A. Slater

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

2012 · Michaela J. Higgins, Danijela Jelovac, et al. · Clinical Cancer Research · 307

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2016 · Roisin M. Connolly, Huili Li, et al. · Clinical Cancer Research · 163

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board

2017 · W. Brian Dalton, Patrick M. Forde, et al. · JCO Precision Oncology · 94

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

2011 · Michaela J. Higgins, Tatiana M. Prowell, et al. · Breast Cancer Research and Treatment · 63

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer

2016 · Heather A. Parsons, Julia A. Beaver, et al. · Clinical Cancer Research · 54

Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer

2013 · Vered Stearns, Lisa K. Jacobs, et al. · Clinical Cancer Research · 27

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

2018 · Cesar A. Santa-Maria, Aditya Bardia, et al. · Breast Cancer Research and Treatment · 24

African American Women Who Receive Primary Anthracycline- and Taxane-Based Chemotherapy for Triple-Negative Breast Cancer Suffer Worse Outcomes Compared With White Women

2009 · Ani Balmanoukian, Zhe Zhang, et al. · Journal of Clinical Oncology · 21

Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer.

2013 · Roisin M. Connolly, Rachel C. Jankowitz, et al. · Cancer Research · 15

Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.

2014 · Roisin M. Connolly, Rachel Catherine Jankowitz, et al. · Journal of Clinical Oncology · 4

Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.

2013 · Aditya Bardia, Cesar Augusto Santa-Maria, et al. · Journal of Clinical Oncology · 4

Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.

2010 · V. Stearns, L. K. Jacobs, et al. · Journal of Clinical Oncology · 4

Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC).

2011 · M. J. Higgins, D. Jelovac, et al. · Journal of Clinical Oncology · 3

A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial.

2014 · Cesar Augusto Santa-Maria, Aditya Bardia, et al. · Journal of Clinical Oncology · 1

A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer.

2010 · M. J. Higgins, T. M. Prowell, et al. · Journal of Clinical Oncology · 1

Supplementary Figure 2 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Figure 4 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Figure 3 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Figure 5 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Table 2 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Table 3 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Table 1 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Figure 1 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Table and Figure Legends from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Supplementary Figure 4 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

2023 · Roisin M. Connolly, Huili Li, et al.

Works count: 35

Citation count: 785

H-index: 9

I10-index: 9